Sangamo Therapeutics Inc.

0.82
-0.04 (-4.35%)
At close: Mar 28, 2025, 3:59 PM
0.84
2.14%
After-hours: Mar 28, 2025, 06:51 PM EDT
-4.35%
Bid 0.81
Market Cap 184.78M
Revenue (ttm) 64.39M
Net Income (ttm) -109.11M
EPS (ttm) -0.49
PE Ratio (ttm) -1.68
Forward PE -5.19
Analyst Buy
Ask 0.84
Volume 1,859,094
Avg. Volume (20D) 5,966,196
Open 0.85
Previous Close 0.86
Day's Range 0.82 - 0.85
52-Week Range 0.30 - 3.18
Beta 1.50

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2000
Employees 183
Stock Exchange NASDAQ
Ticker Symbol SGMO
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 386.44% from the latest price.

Stock Forecasts
1 week ago
+2.94%
Sangamo Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
2 months ago
-56.41%
Sangamo Therapeutics shares are trading lower after Wells Fargo cut its price target on the stock from $3 to $2.